Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 study of Replagal in treatment-naive Chinese patients with Fabry disease
2022-004246-35Phase 3
- Sponsor
- Takeda
- Start
- Jun 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of agalsidase alfa in Fabry disease (FD), sponsored by Takeda. Primary endpoint: Number of participants with serious treatment-emergent adverse events.
02
Drugs
agalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2022-004246-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-004246-35.